Joyce O'Shaughnessy
Baylor University Medical Center
PathologyOncologyMetastatic breast cancerBreast cancerMedicine
What is this?
Publications 370
#1Peter E. Sifneos (QMUL: Queen Mary University of London)H-Index: 99
#2Rebecca DentH-Index: 29
Last. Joyce O'ShaughnessyH-Index: 49
view all 3 authors...
#1Nicholas J. RobertH-Index: 44
#2Joyce O'Shaughnessy (Baylor University Medical Center)H-Index: 49
Last. Anita Fung (Genentech)H-Index: 1
view all 7 authors...
e12648Background: The real-world risk of disease recurrence in patients with HER2+ early breast cancer who achieved pCR after receipt of nPT-based regimens and aT is unclear. Methods: Women with HE...
#1Heather Beckwith (UMN: University of Minnesota)H-Index: 5
#2Diana C. MedgyesyH-Index: 7
Last. Jennifer M. Specht (UW: University of Washington)H-Index: 16
view all 20 authors...
TPS1104Background: LIV-1 is a highly prevalent transmembrane protein in breast cancer cells. Ladiratuzumab vedotin (LV), SGN-LIV1A, is an investigational antibody-drug conjugate (ADC) that targets ...
#1Sanjeev Balu (Novartis)
#2Joyce O'Shaughnessy (Baylor University Medical Center)H-Index: 49
view all 5 authors...
e13059Background: Ribociclib and abemaciclib in combination with endocrine therapy have demonstrated survival benefit in women with HR-positive/HER2-negative mBC. This study assessed early real-wor...
#1K GelmonH-Index: 74
#2Peter A. Fasching (FAU: University of Erlangen-Nuremberg)H-Index: 75
Last. Joyce O'Shaughnessy (Baylor University Medical Center)H-Index: 49
view all 10 authors...
1087Background: OlympiAD (NCT02000622) demonstrated the benefit of olaparib over standard of care in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) and germline BRCA mutat...
#1Sami DiabH-Index: 17
#2Matei P. Socoteanu (Texas Oncology)H-Index: 2
view all 12 authors...
#1Joyce O'Shaughnessy (Texas Oncology)H-Index: 49
#2Rebecca L. Moroose (University of Florida Health)H-Index: 9
Last. Michael L. MeyersH-Index: 6
view all 15 authors...
1014Background: Chemotherapy remains as the only standard treatment option for aTNBC in second and subsequent lines. Entinostat (ENT) is an oral, class I-selective histone deacetylase inhibitor, th...
#1Joyce O'Shaughnessy (Baylor University Medical Center)H-Index: 49
view all 16 authors...
ONCOLOGY® recently sat down with Joyce A. O’Shaughnessy, MD, to discuss the recent trends in breast cancer treatment and the avalanche of agents moving through the development pipeline that have the potential to redefine the accepted standards of care.